Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy

@article{Raymond2012EpidermalGF,
  title={Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy},
  author={Eric Raymond and Sandrine J. Faivre and Jean Pierre Armand},
  journal={Drugs},
  year={2012},
  volume={60},
  pages={15-23}
}
Increasing knowledge of the structure and function of the epidermal growth factor receptor (EGFR) subfamily of tyrosine kinases and of their role in the initiation and progression of various cancers has, in recent years, provided the impetus for a substantial research effort aimed at developing new anticancer therapies that target specific components of the EGFR signal transduction pathway. Selective compounds have been developed that target either the extracellular ligand-binding region of the… Expand
PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor
TLDR
The effects of genetic variants (somatic and germline) in the treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKI) and the pharmacogenomics overview of EGFR in humans are focused on. Expand
Mechanism and Therapeutic Potential of Statin-Mediated Inhibition of Tyrosine Kinase Receptors
Receptor tyrosine kinases (RTK) are key regulators of growth, differentiation and survival of epithelial cells and play a significant role in the development and progression of cancers derived fromExpand
Tyrosine kinase, aurora kinase and leucine aminopeptidase as attractive drug targets in anticancer therapy - characterisation of their inhibitors.
TLDR
This review presents the clinical outcomes of selected inhibitors, argues the safety of drug usage in human volunteers and discusses classification of these enzymes, biochemistry as well as their role in the cell cycle under normal conditions and during cancerogenesis. Expand
EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells.
TLDR
It may be of value to simultaneously combine multiple EGFR inhibitors or use EGFR inhibitor with regulators of other important cancer phenotype regulating molecules, such as STAT3, or involved in important processes such as DNA repair. Expand
Autophosphorylation activation and inhibition by curcumin of the epidermal growth factor receptor reconstituted in liposomes
TLDR
Proteoliposomes can be used as a systematic screening tool for membrane receptor modulators, which are potential drug candidates, and is believed to be a convenient tool to both qualitatively and quantitatively elucidate the mechanism of activation and inhibition of EGFR. Expand
33 EGFR as a therapeutic target in glioblastoma
The tyrosine kinase receptor epidermal growth factor receptor (EGFR) can be activated by several ligands, thus triggering downstream pathways regulating cell growth and survival. Its dysregula tionExpand
Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent
TLDR
A potent EGFR inhibitor (compound A-10) is identified against drug-resistant EGFR through fragment-based drug design and showed at least 30-fold more potency against EGFR T790M than the two control molecules erlotinib and gefitinib in vitro. Expand
Emerging combination therapies to overcome resistance in EGFR-driven tumors
TLDR
Some of the mechanisms of resistance to EGFR inhibitors are described and the main innovations attempting to overcome these drawbacks are reviewed. Expand
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker
TLDR
The present study investigates the cytotoxicity of allitinib in a large panel of human cancer-derived cell lines and correlates its efficacy to the mutational status of the EGFR, KRAS, BRAF, PI3KCA and PTEN genes and suggests that prevalent KRAS mutations constitute potential predictive biomarkers for allit inib response. Expand
EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180
TLDR
A novel mechanism by which EG FRvIII drives glioma tumorigenesis and invasion through PKA-dependent phosphorylation of Dock180 is described, thereby suggesting that targeting EGFRvIII-PKA-Dock180-Rac1 signaling axis could provide a novel pathway to develop potential therapeutic strategies for malignant gliomas. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.
TLDR
Although their cytotoxic and cytostatic potential has been proven, they are not likely to replace standard chemotherapy regimens as single-agent, first-line therapeutics Instead, their promising additive and synergistic antitumour effects in combination with standard chemotherapeutics suggest that these novel agents will find their greatest utility and efficacy in conjunction with existing anticancer agents. Expand
Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives.
  • G. Kelloff, J. R. Fay, +4 authors C. Sigman
  • Chemistry, Medicine
  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 1996
TLDR
Several classes of specific EGFR inhibitors have been synthesized recently, including structures such as benzylidene malononitriles, dianilinophthalimides, quinazolines, pyrimidines, [(alkylamino)methyl]-acrylophenones, enollactones, dihydroxybenzylaminosalicylates, aminoflavones, and tyrosine analogue-containing peptides. Expand
Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.
  • D. W. Fry
  • Biology, Medicine
  • Pharmacology & therapeutics
  • 1999
TLDR
The justification for targeting the EGFR family for cancer therapeutics is addressed, some of the more promising kinase inhibitors that are in development are highlighted, and new structural classes have emerged that exhibit enormous improvements with regard to potency, specificity, and in vitro and in vivo activity. Expand
EGF receptor.
  • A. Wells
  • Medicine
  • The international journal of biochemistry & cell biology
  • 1999
TLDR
In addition to being implicated in organ morphogenesis, maintenance and repair, upregulated EGFR signaling has been correlated in a wide variety of tumors with progression to invasion and metastasis, and are targets for therapeutic interventions in wound repair and cancer. Expand
Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells.
TLDR
The EGFR tyrosine kinase inhibitor PD 153035 induces cytostasis and caspase-dependent apoptosis in EGFR ligand-dependent colon cancer cell lines and encourages further investigation of EGFR Tyrosine Kinase inhibitors for treatment of colorectal neoplasms. Expand
The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases.
  • A. Bridges
  • Chemistry, Medicine
  • Current medicinal chemistry
  • 1999
TLDR
Inhibitors with acrylamides at these positions proved to be irreversible alkylating agents for both EGFr and erbB-2 with cellular inhibitory activities in the low nanomolar range, and very potent in vivo antitumour activity. Expand
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
TLDR
It is demonstrated that oral administration of an EGF-R tyrosine kinase inhibitor decreased growth and metastasis of human pancreatic cancer growing orthotopically in nude mice and increased survival. Expand
Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.
TLDR
It is reported that a human colorectal carcinoma cell line, DiFi, can be induced to undergo G1 cell cycle arrest and programmed cell death (apoptosis) when cultured with mAb 225 at concentrations that saturate EGF receptors, and that a signal transduction pathway shared by receptors for insulin/IGF-1 and EGF may be involved in regulating apoptosis triggered by blockade of the EGF receptor. Expand
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.
  • J. Mendelsohn
  • Medicine, Biology
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
Monoclonal antibody (mAb) 225 against the human epidermal growth factor receptor blocks activation of receptor tyrosine kinase. This retards or arrests cell cycle progression, with accumulation ofExpand
The epidermal growth factor receptor and its inhibition in cancer therapy.
  • J. Woodburn
  • Biology, Medicine
  • Pharmacology & therapeutics
  • 1999
TLDR
The complex nature of EGFR biology allows for potential opportunities for EGFR inhibitors in a number of areas of cancer therapy, including proliferative, angiogenic, invasive, and metastatic aspects. Expand
...
1
2
3
4
...